Ethical and policy issues relating to progenitor-cell-based strategies for prevention of atherosclerosis

S. Matthew Liao, Pascal Goldschmidt-Clermont, Jeremy Sugarman, Hilary Bok, Haywood Brown, R. Alta Charo, Ruth Faden, Joshua Hare, Jeffrey Kahn, Joanne Kurtzberg, Kenneth G. Manton, Jonathan Moreno, Hasan Shanawani, Daniel P. Sulmasy, Holly Taylor, Laurie Zoloth

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To examine important ethical and societal issues relating to the use of progenitor-cell-based strategies for disease prevention, particularly atherosclerosis. Background: Several nascent lines of evidence suggest the feasibility of using progenitor cells to reverse the health consequence of atherosclerosis. Such potential uses of progenitor cells are scientifically exciting, yet they raise important ethical and societal issues. Method: The Working Group on Ethics of Progenitor Cell-based Strategies for Disease Prevention met to discuss the relevant issues. Several drafts of a report were then circulated to the entire Working Group for comments until a consensus was reached. Results: Scientific evidence suggests the appropriateness of using progenitor-cell-based strategies for some rare conditions involving atherosclerosis, but additional preclinical data are needed for other, more prevalent conditions before human trials begin. All such trials raise a set of ethical issues, especially since trials aimed at prevention rather than treatment may involve persons who do not yet have disease but will be exposed to the risks of interventions. In addition, enrolment in prevention trials may be hazardous and harmful if participants erroneously believe experimental interventions will necessarily prevent disease. Finally, given the high prevalence of atherosclerosis, there are some important public policy implications of taking such an approach to prevention, including the sources of progenitor cells for such interventions as well as the allocation of health resources. Conclusion: Potential uses of progenitor-cell-based strategies for preventing atherosclerosis must be considered in the context of a range of social and ethical issues.

Original languageEnglish
Pages (from-to)643-646
Number of pages4
JournalJournal of Medical Ethics
Volume33
Issue number11
DOIs
StatePublished - Nov 1 2007
Externally publishedYes

Fingerprint

Ethics
Atherosclerosis
Stem Cells
Disease
working group
health consequences
evidence
Resource Allocation
Health Resources
public policy
Public Policy
moral philosophy
Cells
Ethical Issues
Policy Issues
human being
health
resources
Health

ASJC Scopus subject areas

  • Nursing(all)
  • Medicine (miscellaneous)
  • Social Sciences (miscellaneous)

Cite this

Liao, S. M., Goldschmidt-Clermont, P., Sugarman, J., Bok, H., Brown, H., Alta Charo, R., ... Zoloth, L. (2007). Ethical and policy issues relating to progenitor-cell-based strategies for prevention of atherosclerosis. Journal of Medical Ethics, 33(11), 643-646. https://doi.org/10.1136/jme.2006.017251

Ethical and policy issues relating to progenitor-cell-based strategies for prevention of atherosclerosis. / Liao, S. Matthew; Goldschmidt-Clermont, Pascal; Sugarman, Jeremy; Bok, Hilary; Brown, Haywood; Alta Charo, R.; Faden, Ruth; Hare, Joshua; Kahn, Jeffrey; Kurtzberg, Joanne; Manton, Kenneth G.; Moreno, Jonathan; Shanawani, Hasan; Sulmasy, Daniel P.; Taylor, Holly; Zoloth, Laurie.

In: Journal of Medical Ethics, Vol. 33, No. 11, 01.11.2007, p. 643-646.

Research output: Contribution to journalArticle

Liao, SM, Goldschmidt-Clermont, P, Sugarman, J, Bok, H, Brown, H, Alta Charo, R, Faden, R, Hare, J, Kahn, J, Kurtzberg, J, Manton, KG, Moreno, J, Shanawani, H, Sulmasy, DP, Taylor, H & Zoloth, L 2007, 'Ethical and policy issues relating to progenitor-cell-based strategies for prevention of atherosclerosis', Journal of Medical Ethics, vol. 33, no. 11, pp. 643-646. https://doi.org/10.1136/jme.2006.017251
Liao SM, Goldschmidt-Clermont P, Sugarman J, Bok H, Brown H, Alta Charo R et al. Ethical and policy issues relating to progenitor-cell-based strategies for prevention of atherosclerosis. Journal of Medical Ethics. 2007 Nov 1;33(11):643-646. https://doi.org/10.1136/jme.2006.017251
Liao, S. Matthew ; Goldschmidt-Clermont, Pascal ; Sugarman, Jeremy ; Bok, Hilary ; Brown, Haywood ; Alta Charo, R. ; Faden, Ruth ; Hare, Joshua ; Kahn, Jeffrey ; Kurtzberg, Joanne ; Manton, Kenneth G. ; Moreno, Jonathan ; Shanawani, Hasan ; Sulmasy, Daniel P. ; Taylor, Holly ; Zoloth, Laurie. / Ethical and policy issues relating to progenitor-cell-based strategies for prevention of atherosclerosis. In: Journal of Medical Ethics. 2007 ; Vol. 33, No. 11. pp. 643-646.
@article{0c35bb80e58c4e2fbae5776b1d6c4369,
title = "Ethical and policy issues relating to progenitor-cell-based strategies for prevention of atherosclerosis",
abstract = "Objective: To examine important ethical and societal issues relating to the use of progenitor-cell-based strategies for disease prevention, particularly atherosclerosis. Background: Several nascent lines of evidence suggest the feasibility of using progenitor cells to reverse the health consequence of atherosclerosis. Such potential uses of progenitor cells are scientifically exciting, yet they raise important ethical and societal issues. Method: The Working Group on Ethics of Progenitor Cell-based Strategies for Disease Prevention met to discuss the relevant issues. Several drafts of a report were then circulated to the entire Working Group for comments until a consensus was reached. Results: Scientific evidence suggests the appropriateness of using progenitor-cell-based strategies for some rare conditions involving atherosclerosis, but additional preclinical data are needed for other, more prevalent conditions before human trials begin. All such trials raise a set of ethical issues, especially since trials aimed at prevention rather than treatment may involve persons who do not yet have disease but will be exposed to the risks of interventions. In addition, enrolment in prevention trials may be hazardous and harmful if participants erroneously believe experimental interventions will necessarily prevent disease. Finally, given the high prevalence of atherosclerosis, there are some important public policy implications of taking such an approach to prevention, including the sources of progenitor cells for such interventions as well as the allocation of health resources. Conclusion: Potential uses of progenitor-cell-based strategies for preventing atherosclerosis must be considered in the context of a range of social and ethical issues.",
author = "Liao, {S. Matthew} and Pascal Goldschmidt-Clermont and Jeremy Sugarman and Hilary Bok and Haywood Brown and {Alta Charo}, R. and Ruth Faden and Joshua Hare and Jeffrey Kahn and Joanne Kurtzberg and Manton, {Kenneth G.} and Jonathan Moreno and Hasan Shanawani and Sulmasy, {Daniel P.} and Holly Taylor and Laurie Zoloth",
year = "2007",
month = "11",
day = "1",
doi = "10.1136/jme.2006.017251",
language = "English",
volume = "33",
pages = "643--646",
journal = "Journal of Medical Ethics",
issn = "0306-6800",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Ethical and policy issues relating to progenitor-cell-based strategies for prevention of atherosclerosis

AU - Liao, S. Matthew

AU - Goldschmidt-Clermont, Pascal

AU - Sugarman, Jeremy

AU - Bok, Hilary

AU - Brown, Haywood

AU - Alta Charo, R.

AU - Faden, Ruth

AU - Hare, Joshua

AU - Kahn, Jeffrey

AU - Kurtzberg, Joanne

AU - Manton, Kenneth G.

AU - Moreno, Jonathan

AU - Shanawani, Hasan

AU - Sulmasy, Daniel P.

AU - Taylor, Holly

AU - Zoloth, Laurie

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Objective: To examine important ethical and societal issues relating to the use of progenitor-cell-based strategies for disease prevention, particularly atherosclerosis. Background: Several nascent lines of evidence suggest the feasibility of using progenitor cells to reverse the health consequence of atherosclerosis. Such potential uses of progenitor cells are scientifically exciting, yet they raise important ethical and societal issues. Method: The Working Group on Ethics of Progenitor Cell-based Strategies for Disease Prevention met to discuss the relevant issues. Several drafts of a report were then circulated to the entire Working Group for comments until a consensus was reached. Results: Scientific evidence suggests the appropriateness of using progenitor-cell-based strategies for some rare conditions involving atherosclerosis, but additional preclinical data are needed for other, more prevalent conditions before human trials begin. All such trials raise a set of ethical issues, especially since trials aimed at prevention rather than treatment may involve persons who do not yet have disease but will be exposed to the risks of interventions. In addition, enrolment in prevention trials may be hazardous and harmful if participants erroneously believe experimental interventions will necessarily prevent disease. Finally, given the high prevalence of atherosclerosis, there are some important public policy implications of taking such an approach to prevention, including the sources of progenitor cells for such interventions as well as the allocation of health resources. Conclusion: Potential uses of progenitor-cell-based strategies for preventing atherosclerosis must be considered in the context of a range of social and ethical issues.

AB - Objective: To examine important ethical and societal issues relating to the use of progenitor-cell-based strategies for disease prevention, particularly atherosclerosis. Background: Several nascent lines of evidence suggest the feasibility of using progenitor cells to reverse the health consequence of atherosclerosis. Such potential uses of progenitor cells are scientifically exciting, yet they raise important ethical and societal issues. Method: The Working Group on Ethics of Progenitor Cell-based Strategies for Disease Prevention met to discuss the relevant issues. Several drafts of a report were then circulated to the entire Working Group for comments until a consensus was reached. Results: Scientific evidence suggests the appropriateness of using progenitor-cell-based strategies for some rare conditions involving atherosclerosis, but additional preclinical data are needed for other, more prevalent conditions before human trials begin. All such trials raise a set of ethical issues, especially since trials aimed at prevention rather than treatment may involve persons who do not yet have disease but will be exposed to the risks of interventions. In addition, enrolment in prevention trials may be hazardous and harmful if participants erroneously believe experimental interventions will necessarily prevent disease. Finally, given the high prevalence of atherosclerosis, there are some important public policy implications of taking such an approach to prevention, including the sources of progenitor cells for such interventions as well as the allocation of health resources. Conclusion: Potential uses of progenitor-cell-based strategies for preventing atherosclerosis must be considered in the context of a range of social and ethical issues.

UR - http://www.scopus.com/inward/record.url?scp=36048934256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36048934256&partnerID=8YFLogxK

U2 - 10.1136/jme.2006.017251

DO - 10.1136/jme.2006.017251

M3 - Article

VL - 33

SP - 643

EP - 646

JO - Journal of Medical Ethics

JF - Journal of Medical Ethics

SN - 0306-6800

IS - 11

ER -